Founded In 2009Olymvax Biopharmaceuticals Incis A National High Tech Enterprisefocusing On The R&Dproduction And Marketing Of Human Use Vaccinesthe Factory Covers An Area Of 52666 Square Meterswith 40 000 Square Metersgmp Facilityadhering To The Business Philosophy Ofstrengthening Managementcommitting To Improvement And Pursuing The Highest Quality Olymvax Aims To Be Aninternationally Well Known And Domestically Leadingvaccine Supplierthe Construction And Management Of The Production Infrastructure Conforms To Chinese Gmp 2010And Is Designed Following Euro American Advanced Criteriapreparing For The Global Marketing Of Productswhen It Comes To R&Dolymvax Has Set Up An International Strategy On Business Development And Initiated Various Projects Around This Goalup To Datethe Company Has Cooperated With Entities With Strong Scientific Ability Around The World To Develop Both First Inclass Vaccines And Vaccines Most In Needolymvax Is Keeping Integrating Global Resourcesmaintaining Cooperation With All Partiesstriving To Achieve Technological Breakthroughs For The Development Of Vaccines By Now Olymvax Has Sucessfully Launched 2 Productstetanus Vaccine And Haemophilus Influenzae B Vaccinestill Numerous Vaccines Are In The Pipelineincluding Recombinant Staphylococcus Aureus Vaccine Which Is In A Phase Ii Clinical Trail And Group A Streptococcus Vaccineas Well As Streptococcus Pneumoniae Vaccinepertussis Vaccine Etc
